Siemens Healthineers Annual Shareholders’ Meeting approves all agenda items by a large majority

Erlangen/Munich, Germany

|2021-02-12

  • Dividend of EUR 0.80 per share for fiscal year 2020
  • Peer Schatz elected as new member of the Supervisory Board

This year’s Annual Shareholders’ Meeting of Siemens Healthineers AG has approved all agenda items by a large majority. At Friday’s meeting, which was held virtually due to the COVID-19 pandemic, shareholders accepted the recommendation of the Managing Board and Supervisory Board to pay a dividend of EUR 0.80 per share for the fiscal year 2020. The dividend thus remains stable at the previous year’s level. At the same time, the actions of the Managing and Supervisory Boards in the past financial year were ratified by a large majority.

Peer Schatz was also elected a new member of the Supervisory Board of Siemens Healthineers AG. “Peer Schatz is an outstanding entrepreneur personality as well as one of the most internationally distinguished and recognized diagnostics experts. We look forward to working together with him in the future,” said Prof. Dr. Ralf P. Thomas, Chairman of the Supervisory Board of Siemens Healthineers AG. With the election of Peer Schatz, the board now has ten members.

The meeting was followed by up to around 1,700 people. Around 100 questions were answered. The detailed voting results are available at https://www.corporate.siemens-healthineers.com/investor-relations/hv.



Siemens Healthineers AG (listed in Frankfurt, Germany: SHL) is shaping the future of Healthcare. As a leading medical technology company headquartered in Erlangen, Germany, Siemens Healthineers enables healthcare providers worldwide through its regional companies to increase value by empowering them on their journey towards expanding precision medicine, transforming care delivery, improving the patient experience, and digitalising healthcare. Siemens Healthineers is continuously developing its product and service portfolio, with AI-supported applications and digital offerings that play an increasingly important role in the next generation of medical technology. These new applications will enhance the company’s foundation in in-vitro diagnostics, image-guided therapy, and in-vivo diagnostics. Siemens Healthineers also provides a range of services and solutions to enhance healthcare providers’ ability to provide high-quality, efficient care to patients. In fiscal 2020, which ended on September 30, 2020, Siemens Healthineers, which has approximately 54,000 employees worldwide, generated revenue of €14.5 billion and adjusted EBIT of €2.2 billion. Further information is available at www.siemens-healthineers.com.


Stefan Schmidt
Karlheinz Kaske Straße 5
91052 Erlangen
Germany

+49 152 02307361
stefanssschmidt@siemens-healthineers.com
Twitter: @stefans_sts

Philipp Grontzki
Karlheinz Kaske Straße 5
91052 Erlangen
Germany

+49 152 03350194
philipp.grontzki@siemens-healthineers.com
Twitter: @PGrontzki

Ulrich Kuenzel
Karlheinz Kaske Straße 5
91052 Erlangen
Germany

+49 162 2433492
ulrich.kuenzel@@siemens-healthineers.com
Twitter: @ugsku